| Literature DB >> 26635719 |
Marianne David1, Hubert R Dinse2, Tina Mainka3, Martin Tegenthoff4, Christoph Maier1.
Abstract
Achieving perceptual gains in healthy individuals or facilitating rehabilitation in patients is generally considered to require intense training to engage neuronal plasticity mechanisms. Recent work, however, suggested that beneficial outcome similar to training can be effectively acquired by a complementary approach in which the learning occurs in response to mere exposure to repetitive sensory stimulation (rSS). For example, high-frequency repetitive sensory stimulation (HF-rSS) enhances tactile performance and induces cortical reorganization in healthy subjects and patients after stroke. Patients with complex regional pain syndrome (CRPS) show impaired tactile performance associated with shrinkage of cortical maps. We here investigated the feasibility and efficacy of HF-rSS, and low-frequency rSS (LF-rSS) to enhance tactile performance and reduce pain intensity in 20 patients with CRPS type I. Intermittent high- or low-frequency electrical stimuli were applied for 45 min/day to all fingertips of the affected hand for 5 days. Main outcome measures were spatial two-point-discrimination thresholds and mechanical detection thresholds measured on the tip of the index finger bilaterally. Secondary endpoint was current pain intensity. All measures were assessed before and on day 5 after the last stimulation session. HF-rSS applied in 16 patients improved tactile discrimination on the affected hand significantly without changes contralaterally. Current pain intensity remained unchanged on average, but decreased in four patients by ≥30%. This limited pain relief might be due to the short stimulation period of 5 days only. In contrast, after LF-rSS, tactile discrimination was impaired in all four patients, while detection thresholds and pain were not affected. Our data suggest that HF-rSS could be used as a novel approach in CRPS treatment to improve sensory loss. Longer treatment periods might be required to induce consistent pain relief.Entities:
Keywords: CRPS; complex regional pain syndrome; cortical reorganization; rSS; repetitive sensory stimulation; tactile performance
Year: 2015 PMID: 26635719 PMCID: PMC4648023 DOI: 10.3389/fneur.2015.00242
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Patients characteristics.
| Patient | Age (years) | Gender | Handedness | Affected hand | Inciting event | With/without surgery before onset | Disease duration (months) | Positive scintigraphy | Finger-palm-distance (cm) | Current pain | Average pain (last 4 weeks) | Sensory signs | Vasomotor signs | Sudormotor signs/edema | Motor/trophic signs | Current medication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 49 | F | R | R | Fract. | − | 9 | + | 3 | 7 | 7 | + | + | + | + | Metamizol, AC, TCA |
| 2 | 46 | M | R | R | Fract. | + | 5 | + | 0 | 0 | 7 | + | + | + | + | Metamizol |
| 3 | 57 | F | R | L | Surg. | + | 12 | + | 0 | 5 | 6 | + | − | + | + | Metamizol, AC |
| 4 | 28 | F | R | L | Trau. | + | 4 | n/a | 11 | 3 | 5 | + | + | − | + | Metamizol, AC, Opioids-III |
| 5 | 59 | F | R | R | Trau. | + | 6 | + | 4 | 3 | − | + | − | − | + | Opioids-II, NSAID |
| 6 | 70 | F | R | R | Surg. | + | 11 | + | 5 | 3 | 4 | + | + | + | + | Paracetamol |
| 7 | 58 | F | R | L | Fract. | − | 12 | n/s | 5 | 5 | 5 | + | − | − | + | Metamizol |
| 8 | 58 | M | R | L | Surg. | + | 4 | + | 4 | 1 | 6 | + | − | + | + | Metamizol, AC, Opioids-III, NSAID |
| 9 | 60 | F | R | L | Fract. | + | 2 | + | 5 | 1 | 10 | + | + | + | + | Metamizol, NSAID |
| 10 | 60 | F | R | R | Fract. | + | 15 | + | 4 | 4 | 6 | + | + | + | + | AC, Opioids-III |
| 11 | 63 | F | R | L | Fract. | − | 5 | + | 3.5 | 7 | 8 | + | − | + | + | Metamizol, SNRI |
| 12 | 52 | M | R | R | Fract. | − | 14 | n/s | 2.5 | 6 | 3 | + | + | + | + | NSAID |
| 13 | 52 | M | R | L | Fract. | + | 27 | + | 11 | 5 | 5 | + | + | + | + | Metamizol, AC, Flupirtin |
| 14 | 51 | M | R | L | Fract. | − | 4 | + | 6 | 3 | 4 | + | + | + | + | NSAID, TCA |
| 15 | 60 | M | R | R | Fract. | + | 8 | + | 2 | 2 | 9 | + | + | + | + | Metamizol, AC |
| 16 | 41 | M | R | R | Trau. | + | 5 | + | 2 | 2 | 2 | + | − | + | + | Metamizol |
| 17 | 71 | M | R | L | Fract. | + | 6 | + | 6 | 6 | 6 | + | + | + | + | AC, Opioids-III, NSAID |
| 18 | 53 | M | R | L | Fract. | − | 12 | + | 1 | 4 | 5 | + | − | + | + | Opioids-II, NSAID |
| 19 | 58 | F | R | R | Surg. | + | 9 | − | 3 | 3 | 7 | + | − | + | + | AC, Opioids-III, NSAID, Flupirtin |
| 20 | 58 | M | L | L | Fract. | + | 4 | + | 3 | 0 | 5 | + | + | + | + | NSAID |
F, female; M, male; R, right; L, left; Fract, fracture; surg, handsurgery for preceding disease (e.g., M. Dupuytren, rhizarthritis); trau, soft tissue trauma (e.g., incision wounds, crush injury), bone metabolism; +, increased periarticular tracer uptake in 3-phase bone scintigraphy; n/a, not available; n/s, later than 8 months post inciting event; AC, anticonvulsant; TCA, tricyclic antidepressant; SNRI, serotonin–norepinephrine reuptake inhibitor; NSAID, non-steroidal anti-inflammatory drug; opioids-II, WHO-class II opioid (e.g., Tramadol); opioids-III, WHO-class III opioid (e.g., Tapentadol).
.
.
.
.
Figure 1Two-point-discrimination thresholds (2PDTH, mean ± SE) of the affected and non-affected hand pre and post HF-rSS. **p < 0.01.
Figure 2Mechanical detection thresholds (MDT, mean ± SE) of the affected and non-affected hand pre and post HF-rSS. **p < 0.01.
Partial correlation coefficients of tactile performance parameters and pain intensity, with age as control variable.
| Parameter | Disease duration | 2PDTH affected hand, pre | 2PDTH affected hand, post | Δ 2PDTH affected hand | MDT affected hand, pre | MDT affected hand, post | Δ MDT affected hand | Current pain, pre | Current pain, post | Δ current pain |
|---|---|---|---|---|---|---|---|---|---|---|
| Disease duration | 0.219 | −0.146 | −0.512 | −0.086 | 0.477 | 0.733 | 0.463 | 0.429 | −0.028 | |
| 2PDTH affected hand, pre | 0.219 | 0.840 | 0.082 | −0.161 | 0.224 | 0.465 | 0.276 | −0.065 | −0.323 | |
| 2PDTH affected hand, post | −0.146 | 0.597 | 0.133 | 0.214 | 0.048 | 0.203 | −0.091 | −0.263 | ||
| Δ 2PDTH affected hand | −0.512 | 0.082 | 0.597 | 0.558 | 0.182 | −0.505 | 0.009 | −0.027 | −0.010 | |
| MDT affected hand, pre | −0.086 | −0.161 | 0.133 | 0.558 | 0.695 | −0.257 | 0.118 | −0.112 | −0.373 | |
| MDT affected hand, post | 0.477 | 0.224 | 0.214 | 0.182 | 0.439 | 0.326 | −0.031 | −0.513 | ||
| Δ MDT affected hand | 0.026 | 0.465 | 0.048 | −0.505 | −0.257 | 0.439 | 0.147 | 0.106 | −0.077 | |
| Current pain, pre | 0.463 | 0.276 | 0.203 | 0.009 | 0.118 | 0.326 | 0.147 | 0.653 | −0.307 | |
| Current pain, post | 0.429 | −0.065 | −0.091 | −0.027 | −0.112 | −0.031 | 0.106 | −0.495 | ||
| Δ Current pain | −0.028 | −0.323 | −0.263 | −0.010 | −0.373 | −0.513 | −0.077 | −0.307 | 0.495 |
2PDTH, two-point-discrimination threshold; MDT, mechanical detection threshold.
Δ, % change (pre vs. post).
Bold font indicates significant p values
**p < 0.01, *p < 0.05.
Figure 3Two-point-discrimination thresholds (2PDTH, mean ± SE) of the affected and non-affected hand pre and post LF-rSS.
Figure 4Mechanical detection thresholds (MDT, mean ± SE) of the affected and non-affected hand pre and post LF-rSS.